Age-Related Macular Degeneration (AMD) is a progressive disease that damages the macula, the part of the retina responsible for sharp, central vision. Several treatments exist, including intravitreal injections of anti-vascular endothelial growth factor (VEGF) drugs like Lucentis and Avastin, laser photocoagulation, and photodynamic therapy with Verteporfin. These therapies aim to slow or halt the progression of AMD and preserve vision. In some cases, surgery like a macular translocation or vitrectomy may be necessary.
Age-Related Macular Degeneration (AMD) is a progressive disease that damages the macula, the part of the retina responsible for sharp, central vision. Several treatments exist, including intravitreal injections of anti-vascular endothelial growth factor (VEGF) drugs like Lucentis and Avastin, laser photocoagulation, and photodynamic therapy with Verteporfin. These therapies aim to slow or halt the progression of AMD and preserve vision. In some cases, surgery like a macular translocation or vitrectomy may be necessary.
Poland offers various treatments for Age-Related Macular Degeneration (AMD), including intravitreal injections of anti-VEGF agents like Lucentis and Eylea. These injections help reduce vision loss and even improve vision in some cases. Moreover, photodynamic therapy is an additional treatment employed to delay AMD progression.
Poland's healthcare system has good facilities and skilled professionals. AMD treatments are covered under the National Health Fund for eligible patients.